Equity Analysis /
United States of America

US : Viking Therapeutics, Inc. - VKTX | 3Q21 Update: Dual GLP-1/GIP Agonist Expands Metabolic Portfolio

    Contributors
    Timur Ivannikov
    Ryan Deschner
    CGS-CIMB
    4 November 2021
    Published by